SEROPREVALENCE AND RISK FACTORS ASSOCIATED WITH HPV INFECTIONS AMONG PATIENTS IN KOGI EAST SENATORIAL ZONE
Abstract
Analysis of prevalence and risk factors for Human Papilloma Virus (HPV) is the basis for prophylactic strategies against HPV infections. This study was to determine the seroprevalence of human papillomavirus, sociodemographic and risk factors associated with acquiring the virus among the study population. A total of 195 samples were collected by simple random sampling technique from three major hospitals in the zone. Serum from blood samples was used for ELISA and analyzed for IgM. Overall prevalence of 3.08% (6/195) was established for HPV infection. Patients with early sexual activity and those with multiple sexual partners were likely to be infected than their counterparts with 15.8%: 3/19 (χ 2 =16.4, df=3, p=0.001) and 50%: 2/4 (χ 2 =30.2, df=1, p=0.005) respectively. The infection was more among those who got married at age range of 26-30 years with prevalence of 5.4%: 2/37 (χ 2 =1.30, df = 5, p=0.82). On the basis of sex, female were found to have higher prevalence of 3.6%: 6/167(χ 2 =1.04, df = 1, p=0.6). Subjects with sexually transmitted disease (STD) had a higher prevalence of 8%: 2/25(χ 2 =2.45, df=2, p=0.32). The study shows that infection with HPV was strongly associated with age of sexual debut and number of sexual partners. It also reveals the occurrence of HPV infection in Kogi East, Nigeria. Hence, there is need for routine screening, public education and vaccination to prevent the spread of the virus which is a threat to public health.
References
REFERENCES
Frazer, I. H. (2010). Measuring Serum Antibody to Human Papillomavirus fol¬lowing Infection or Vaccination. Gynecological Oncololgy, 118(1): 8–11.
Gibbs, N.F. (1998). Anogenital Papillomavirus Infections in Children. Curricullar Opinion Pediatry, 10: 393– 397
Vanchiere, J. and Demmer, G. (2004) Human polyomaviruses and papillomaviruses. In: Feigin Cherry, R. J., Demmler, G., and Kaplan, S., (eds). Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: Saunders;1809–1831
Franco, E.L., Duarte-Franco, E., Ferenczy, A. (2001). Cervical Cancer Epidemiology, Prevention and the Role of Human Papillomavirus Infection. Cancer Medical Association Journal, 164: 1017-1025.
Gillison M.L., Disouza G., Wstra W., Sugar E., Xiao W. (2008). Distinct Risk factors profiles from Type 16 Negative Head and Neck Cancer. Journal of National Cancer institute, 100: 407-420.
Watson, M., Saraiya, M. and Wu, X. (2009). Update of HPV-associated Female Genital Cancers in the United States, 1999-2004. Journal of Women Health, 18: 1731-1738.
Sycuro, L.K., Xi, L.F., Hughes, J.P., Feng, Q., Winner, R.L., Lee, S.K., O’Reilly, S., Kiviat, N.B. and Koutsky, L.A. (2008). Persistence of Genital Human Papillomavirus Infection in a Long-term Follow-up Study of Female University Students. Journal of Infectious Diseases, 198: 971–978.
Lee, C.A. (2012). Human Papillomavirus (HPV) and Cervical Cancer. Journal of Insurance Medicne, 43: 178–181.
Molano, M., Van den B.A. and Plummer M. (2003). Determinants of Clearance of Human Papillomavirus Infections in Colombian Women with Normal Cytology: a Population-based, 5-year follow-up study. American Journal of Epidemiology, 158: 486-494.
Hariri, S., Dunne, E., Mona, S., Unger, E. and Markowitz, L. (2014). Manual for the Surveillance of Vaccine-Preventable Diseases Human Papillomavirus. 5th Edition, 5-7.
Touzé, A., de Sanjosé, S., Coursaget, P., Almirall, M.R., Palacio, V., Meijer, C.J., Kornegay, J., Bosch F.X. (2001). Prevalence of anti-human papillomavirus types 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes. Journal of Clinical Microbiology, 39: 4344–4348.
Aminu, M., Gwafan, J. Z., Inabo , H.I., Oguntayo, A. O., Ella, E.E and Koledade , A. K. (2014). Seroprevalence of human papillomavirus immunoglobulin G antibodies among women presenting at the reproductive health clinic of a university teaching hospital in Nigeria. International Journal of Women’s Health, 6: 479-489.
Di Giuseppe, G., Abbate, R., Liguori, G., Albano, L. and Angelillo, I.F. ( 2008). Human papillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. Britsish Journal of Cancer. 99(2):225-9.
Trim, K. Nagji, N., Elit, L. and Roy, K. (2012). Parental Knowledge, Attitudes and Behav¬iours towards Human Papillomavirus Vaccination for Their Children: a system¬atic review from 2001 to 2011. Obstetician Gynecology International, 92(12): 36.
Dahlstrom, L.A., Tran, T.N., Lundholm, C., Young, C., Sundström, K. and Sparén, P., (2010). Attitudes to HPV vaccination among parents of children aged 12–15 years – a population-based survey in Sweden. International Journal of Cancer, 126: 500–507.
Ezenwa, B.N., Balogun, M.R. and Okafor, I.P. (2013). Mothers’ Human Papilloma Virus Knowledge and Willingness to Vaccinate their Adolescent Daughters in Lagos, Nigeria. International Journal of Women Health, 5: 371–377.
WHO/ICO. (2012). Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Nigeria. Accessed 25th October 2015.
Bruni, L. Barrionuevo-Rosas, L. and Serrano B. (2014). Human Papillomavirus and Related Diseases in Nigeria. ICO Information Centre on HPV and Cancer (ICO, HPV Information Centre).
Sarmukaddam, S. B. and Gerald, S. G. (2006). On Validity of Assumption while determining Sample Size. Indian Journal of commodity medium, 29(2): 2004-2006
Charan, J. and Biswas, T. (2013). How to Calculate Sample Size for different Study Designs in Medical Research. Indian Journal of Psychological Medicine, 35 (2):121-126.
Clarke, Ma, Gage, J.C., Ajenifuja, K.O., Wentzensen, N.A., Adepiti, A.C., Wacholder, S., Burk, R.D. and Schiffman, M. (2011). A Population-Based, Cross-Sectional Study Of Age Specific Risk Factors for High Risk Human Papillomavirus Prevalence in Rural Nigeria. Infectious Agent of Cancer, 6:12.
Salih, M. M., Safi, M. E., Hart, K., Tobi, K. and Adam, I. (2010). Genotypes of Human Papilloma Virus in Sudanese Women with Cervical Pathology. Infectious Agents and Cancer. 5(26): 1750-9378-5-26.
Menéndez, C., Castellsagué, X., Renom, M., Sacarlal, J., Quintó, L., Lloveras, B., Klaustermeier J, Kornegay, J. R., Sigauque, B., Bosch, F. X, and Alonso, P.L. (2010). Prevalence and Risk Factors of Sexually Transmitted Infections and Cervical Neoplasia in Women from a Rural Area of Southern Mozambique. Infectious Diseases in Obstetrics and Gynecology.
Okolo, C., Franceschi, S., Adewole, I., Thomas, J.O., Follen, M., Snijders, P.J., Meijer, C.J. and Clifford, G.M. (2010). Human Papillomavirus Infection In Women with and Without Cervical Cancer In Ibadan, Nigeria. Infectious Agent of Cancer, 5(1): 24.
Zizipho Z. A. Mbulawa, Dianne J. Marais, Leigh F. Johnson, David Coetzee, and Anna-Lise Williamson (2012). Impact of Human Immunodeficiency Virus on the Natural History of Human Papillomavirus Genital Infection in South African Men and Women. The Journal of Infectious Diseases. (206):15–27.
Ma, G.X., Wang, M.Q., Ma, X.S., Shive, S.E., Tan, Y. and Toubbeh, J.I. (2013). Pathways of Cervical Cancer Screening among Chinese Women. International Journal of Womens Health, 5: 351–359.
Wiredu, E. K. and Armah, H. B.(2006). Cancer Mortality Patterns in Ghana: A 10-Year Review of Autopsies and Hospital Mortality. Public Health. (6):159.
Auwal, I.K., Aminu, M., Atanda, A.T., Tukur, J. and Sarkinfada, F. (2013). Prevalence and Risk factors of High Risk Human Papillomavirus Infections among Women attending Gynaecology Clinics in Kano, Northern Nigreia. Bayero Journal of Pure and Applied Sciences, 6(1): 67-71.
Thomas, J.O., Herrero, R., Omigbodun, A.A., Ojemakinde, K., Ajayi, I.O., Fawole, A., Oladepo, O., Smith, J.S., Arslan, A., Munoz, N., Snijders, P.J.,Meijer, C.J and Franceschi,S. (2004). Prevalence Of Papillomavirus Infection In Women In Ibadan, Nigeria: A population-Based Study. British Journal of Cancer, 90: 638 -645.
Sellors, J. W., Karwalajtys, T. L., Kaczorowski, J., Mahony, J. B., Lytwyn, A., Chong, S., Sparrow, J. and Lorincz, A; Survey of HPV in Ontario Women Group. (2003). Incidence, clearance and predictors of human papillomavirus infection in women. Canadian medical association journal.18:(4):421-5.
Helen, Trottier, Salaheddin, Mahmud, José Carlos M Prado, Joao S Sobrinho, Maria C Costa, Thomas E Rohan, Luisa L Villa, Eduardo L Franco (2008). Type)-Specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. The Journal of Infectious Diseases. 197:1436–1447.
Naucler, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., Hansson, B. G., Rylander, E. and Dillner, J. (2007). Human papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer. New England Journal of Medicine.357(16):1589-97.
Schlecht , N. F., Kulaga, S., Robitaille, J., Ferreira, S., Santos, M., Miyamura, R. A., Duarte-Franco, E., Rohan, T. E., Ferenczy, A., Villa, L. L. and Franco, E. L. (2001). Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial Neoplasia. Journal of American Medical Association. 286(24):3106-14.
Tabora, N., Zelaya, A., Bakkers, J., Melchers, W. J. And Ferrera, A. (2005). Chlamydia Trachomatis and Genital Human Papillomavirus Infections in Female University Students in Honduras. American Journal of Tropical Medicine Hygiene. 73:50–53.
Adewuyi, S. A., Shittu, S. O. and Rafindadi, A. H. (2008): Socio-Demographic and Clinicopathologic Characterization of Cervical Cancers in Northern Nigeria. European Journal of Gynaecology. 29(1):61-61.
Thomas, M., Narayan, N., Pim, D., Tomaić, V., Massimi, P., Nagasaka, K., Kranjec, C., Gammoh, N. and Banks, L.(2008). Human Papillomaviruses, Cervical Cancer and Cell Polarity. Oncogene. 27(55):7018-30
Serwadda, D., Wawer, M.J., Shah, K.V., Sewankambo, N.K., Daniel, R., Li, C., Lorincz, A., Meehan, M.P., Wabwire-Mangen, F. and Gray, R.H. (1999). Use of a Hybrid Capture Assay of Self-Collected Vaginal Swabs in rural Uganda for detection of Human Papillomavirus. Journal Infectious Disease, 354:2545—2634.
Gravitt, P., Peyton, C. and Alessi, T. (2002). Improved Amplification of Genital Human Papillomaviruses. Journal of Clinical Microbiology, 38: 357–61
Winkelstein, W. J. R., Edward, J. and Shillitoe R. B. K.J. (1984). Further Comment on Cancer of the Uterine Cervix, Smoking, and Herpesvirus Infections. American Journal of Epidemiology, 119:1
Mbulawa, Z. Z. A., Shalkioyk, C., Hu, N. C., Mairing, T. I., Barnabas, S., Dabee, S., Jaspan, H., Kriek, J. M., Jaumdally, S. Z., Mullar, E., Bekker, L. G, lewiz, D.A, Dietrich, j., Gray, G., Passmore, J. S. and Willianson, A. L. (2018). Human Papillomavirus (HPV) Prevalence in South African Adolescents and Young Woman encourages expanded HPV Vaccination Campaigns. PLos, ONE, 13(1): eo190166.
Matsumoto, K., Yasugi, T., Oki, A., Hoshiai, H., Taketani, Y., Kawana, T. and Yoshikawa, H. (2003). Are Smoking and Chlamydial Infection Risk Factors for CIN? Different Results after Adjustment for HPX DNA and Antibodies. British Journal of Cancer, 89(5): 831-3
Moscick, A. B., Schiffman, M. and Kjaer, S. (2006). Updating the Natural History of HPV and Anogeintal Cancer. Vaccine, 24(3): 42-51.
Simen-Kapeu, K., Yhiskoshi, M., Syrjaneu, S., Diller, J. and Koskela, P. (2008). Smoking Impairs Human Papillous Virus (HPV) Type 16 and 18 Capsids Antibody Response following Natural HPV Infection. Scandinavian Journal of Infectious Diseases, 40(9): 745-751.
Copyright (c) 2020 FUDMA JOURNAL OF SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
FUDMA Journal of Sciences
